Log in

NASDAQ:HARPHarpoon Therapeutics Stock Price, Forecast & News

$11.11
-0.23 (-2.03 %)
(As of 04/5/2020 04:00 PM ET)
Add
Compare
Today's Range
$10.88
Now: $11.11
$11.34
50-Day Range
$10.74
MA: $13.68
$16.32
52-Week Range
$9.77
Now: $11.11
$21.47
Volume42,733 shs
Average Volume82,703 shs
Market Capitalization$277.08 million
P/E RatioN/A
Dividend YieldN/A
Beta0.92
Harpoon Therapeutics, Inc., a clinical-stage immunotherapy company, engages in the development of a novel class of T cell engagers that harness the power of the body's immune system to treat patients suffering from cancer and other diseases in the United States. The company's lead TriTAC product candidate is HPN424 that is in Phase I clinical trial for the treatment of metastatic castration-resistant prostate cancer. It also develops HPN536 for the treatment of ovarian cancer and other MSLN-expressing tumors; HPN217 for the treatment of multiple myeloma; and HPN328 for the treatment of SCLC. The company has a collaboration agreement with AbbVie Biotechnology Ltd. Harpoon Therapeutics, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Read More

Beat the Market (BTM) Rank

Analyst Opinion: 3.5Community Rank: 2.1Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -

Overall Beat the Market Rank

1.45 out of 5 stars


Industry, Sector and Symbol

Industry Biological products, except diagnostic
Sub-IndustryN/A
SectorMedical
Current SymbolNASDAQ:HARP
CUSIPN/A
CIKN/A
Phone650-443-7400

Debt

Price-To-Earnings

Sales & Book Value

Annual Sales$5.78 million
Book Value$3.82 per share

Profitability

Net Income$-55,570,000.00
Net Margins-962.70%

Miscellaneous

Employees45
Market Cap$277.08 million
Next Earnings Date5/14/2020 (Estimated)
OptionableNot Optionable

Receive HARP News and Ratings via Email

Sign-up to receive the latest news and ratings for HARP and its competitors with MarketBeat's FREE daily newsletter.


Harpoon Therapeutics (NASDAQ:HARP) Frequently Asked Questions

How has Harpoon Therapeutics' stock been impacted by COVID-19 (Coronavirus)?

Harpoon Therapeutics' stock was trading at $13.07 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, HARP shares have decreased by 15.0% and is now trading at $11.11. View which stocks have been mosted impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Harpoon Therapeutics?

6 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Harpoon Therapeutics in the last year. There are currently 6 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Harpoon Therapeutics.

When is Harpoon Therapeutics' next earnings date?

Harpoon Therapeutics is scheduled to release its next quarterly earnings announcement on Thursday, May 14th 2020. View our earnings forecast for Harpoon Therapeutics.

How were Harpoon Therapeutics' earnings last quarter?

Harpoon Therapeutics Inc (NASDAQ:HARP) released its earnings results on Thursday, March, 12th. The company reported ($0.58) earnings per share for the quarter, missing the Zacks' consensus estimate of ($0.53) by $0.05. The company had revenue of $2.23 million for the quarter, compared to analyst estimates of $3.53 million. Harpoon Therapeutics had a negative return on equity of 51.51% and a negative net margin of 962.70%. View Harpoon Therapeutics' earnings history.

What price target have analysts set for HARP?

6 equities research analysts have issued 12-month price targets for Harpoon Therapeutics' stock. Their forecasts range from $23.00 to $31.00. On average, they anticipate Harpoon Therapeutics' stock price to reach $26.33 in the next twelve months. This suggests a possible upside of 137.0% from the stock's current price. View analysts' price targets for Harpoon Therapeutics.

Has Harpoon Therapeutics been receiving favorable news coverage?

News stories about HARP stock have been trending very negative this week, InfoTrie reports. The research firm scores the sentiment of press coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Harpoon Therapeutics earned a news impact score of -3.3 on InfoTrie's scale. They also assigned news headlines about the company a news buzz of 0.0 out of 10, meaning that recent press coverage is extremely unlikely to have an effect on the stock's share price in the immediate future. View the latest news aboutHarpoon Therapeutics.

Are investors shorting Harpoon Therapeutics?

Harpoon Therapeutics saw a increase in short interest during the month of March. As of March 13th, there was short interest totaling 289,000 shares, an increase of 12.8% from the February 27th total of 256,100 shares. Based on an average trading volume of 65,700 shares, the short-interest ratio is currently 4.4 days. Currently, 2.1% of the shares of the company are sold short. View Harpoon Therapeutics' Current Options Chain.

Who are some of Harpoon Therapeutics' key competitors?

What other stocks do shareholders of Harpoon Therapeutics own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Harpoon Therapeutics investors own include Alector (ALEC), Editas Medicine (EDIT), Gossamer Bio (GOSS), NVIDIA (NVDA), Advanced Micro Devices (AMD), Activision Blizzard (ATVI), Precision BioSciences (DTIL), Intel (INTC), Kaleido Biosciences (KLDO) and Tcr2 Therapeutics (TCRR).

Who are Harpoon Therapeutics' key executives?

Harpoon Therapeutics' management team includes the following people:
  • Dr. Luke B. Evnin, Chairman (Age 56)
  • Dr. Gerald McMahon, Pres, CEO & Director (Age 64)
  • Dr. Holger Wesche Ph.D., Chief Scientific Officer (Age 51)
  • Dr. Natalie R. Sacks, Chief Medical Offer (Age 54)
  • Ms. Georgia L. Erbez, Chief Financial Officer (Age 52)

When did Harpoon Therapeutics IPO?

(HARP) raised $76 million in an initial public offering (IPO) on Friday, February 8th 2019. The company issued 5,400,000 shares at a price of $13.00-$15.00 per share. Citigroup and Leerink Partners served as the underwriters for the IPO and Canaccord Genuity and Wedbush PacGrow were co-managers.

What is Harpoon Therapeutics' stock symbol?

Harpoon Therapeutics trades on the NASDAQ under the ticker symbol "HARP."

How do I buy shares of Harpoon Therapeutics?

Shares of HARP can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Harpoon Therapeutics' stock price today?

One share of HARP stock can currently be purchased for approximately $11.11.

How big of a company is Harpoon Therapeutics?

Harpoon Therapeutics has a market capitalization of $277.08 million and generates $5.78 million in revenue each year. The company earns $-55,570,000.00 in net income (profit) each year or ($2.55) on an earnings per share basis. Harpoon Therapeutics employs 45 workers across the globe. View additional information about Harpoon Therapeutics.

What is Harpoon Therapeutics' official website?

The official website for Harpoon Therapeutics is http://www.harpoontx.com/.

How can I contact Harpoon Therapeutics?

Harpoon Therapeutics' mailing address is 131 OYSTER POINT BLVD SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The company can be reached via phone at 650-443-7400 or via email at [email protected]

This page was last updated on 4/5/2020 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.

Yahoo Gemini Pixel